#United States #New York City #Genprex #diabetes #Cancer

Genprex's Upcoming Conferences

Genprex, Inc., a clinical-stage gene therapy company, has announced its participation in several key investor and industry conferences in September 2025. These events will provide Genprex an opportunity to showcase its innovative therapies aimed at treating significant medical conditions such as cancer and diabetes.

Conference Details

1. H.C. Wainwright 27th Annual Global Investment Conference
- Location: Lotte New York Palace Hotel, New York City
- Dates: September 8-10, 2025
- Presentation Date: Available on-demand from September 5-10, 2025 for registered investors
- Participants: Ryan Confer (President & CEO), Thomas Gallagher (SVP of Intellectual Property and Licensing)

Mr. Confer is scheduled to present a detailed overview of Genprex's pioneering gene therapies that target cancer and diabetes, with additional opportunities for investors to engage in one-on-one meetings through the conference platform.

2. C3 Davos of Healthcare™ New York Summit at King Faisal Specialist Hospital
- Date: September 8, 2025
- Location: Union League Club, New York City
- Participants: Ryan Confer & Thomas Gallagher

Both executives will be accessible for in-person meetings during this summit, providing investors with an intimate setting to discuss the company's advancements and strategies. Interested parties can reach out to the Genprex team to schedule these meetings via their official contact.

3. Investor Summit Group Q3 Virtual Conference
- Dates: September 16-17, 2025
- Format: Virtual Presentation
- Presenter: Ryan Confer

The virtual platform will allow Ryan Confer to extend insights into Genprex's gene therapy innovations and offer an additional chance for one-on-one discussions post-presentation. A recording of this presentation will subsequently be available on Genprex's website for interested investors.

About Genprex, Inc.

Founded with a vision to transform treatment options, Genprex specializes in the development of gene therapies designed to address critical medical needs especially in cancer and diabetes.

Gene Therapy Approach for Cancer and Diabetes

Genprex's leading technology emphasizes the delivery of disease-fighting genes to patients, leveraging unique methods such as its Oncoprex® Delivery System which utilizes non-viral lipid nanoparticles. This system is designed to introduce therapeutic genes directly into tumor cells, missing critical tumor suppressor proteins in those affected by cancer. Genprex's flagship product, Reqorsa® Gene Therapy, is currently undergoing evaluation for treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Additionally, Genprex's diabetes treatment harnesses an innovative infusion process that utilizes an adeno-associated virus (AAV) vector to deliver essential genes directly to the pancreas. This method aims to transform existing pancreatic alpha cells into insulin-producing beta-like cells, which is a significant breakthrough for patients suffering from Type 1 diabetes.

On the other hand, GPX-002, targeted at Type 2 diabetes, works to rejuvenate exhausted beta cells, employing a mechanism that helps these cells regain function. Genprex's approach stands out not just for its medical efficacy but also for its potential to address large patient populations lacking effective treatment options.

Investor Engagement

Genprex actively encourages interested investors and stakeholders to stay updated about the company's progress and announcements by visiting their website. They can also register for email alerts and follow the company on various social media platforms for timely updates.

In closing, Genprex is poised to make a significant impact in the healthcare landscape with its advancements in gene therapy, as it continues to pave the way for new treatment paradigms in cancer and diabetes management.

Forward-Looking Statements Disclaimer

Please note that any statements that are not historical facts are considered